Literature DB >> 17516028

Organotypic distribution of stem cell markers in formalin-fixed brain harboring glioblastoma multiforme.

Rudolph J Schrot1, Joyce H Ma, Claudia M Greco, Angelo D Arias, James M Angelastro.   

Abstract

The role of stem cells in the origin, growth patterns, and infiltration of glioblastoma multiforme is a subject of intense investigation. One possibility is that glioblastoma may arise from transformed stem cells in the ventricular zone. To explore this hypothesis, we examined the distribution of two stem cell markers, activating transcription factor 5 (ATF5) and CD133, in an autopsy brain specimen from an individual with glioblastoma multiforme. A 41-year-old male with a right posterior temporal glioblastoma had undergone surgery, radiation, and chemotherapy. The brain was harvested within several hours after death. After formalin fixation, sectioning, and mapping of tumor location in the gross specimen, histologic specimens were prepared from tumor-bearing and grossly normal hemispheres. Fluorescence immunohistochemistry and colorimetric staining were performed for ATF5 and CD133. Both markers co-localized to the ependymal and subependymal zones on the side of the tumor, but not in the normal hemisphere or more rostrally in the affected hemisphere. ATF5 staining was especially robust within the diseased hemisphere in histologically normal ependyma. To our knowledge, this is the first in situ demonstration of stem cell markers in whole human brain. These preliminary results support the hypothesis that some glioblastomas may arise from the neurogenic zone of the lateral ventricle. The robust staining for ATF5 and CD133 in histologically normal ventricular zone suggests that an increase in periventricular stem cell activity occurred in this patient on the side of the tumor, either as a localized response to brain injury or as an integral component of oncogenesis and tumor recurrence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17516028     DOI: 10.1007/s11060-007-9401-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Regulated expression of ATF5 is required for the progression of neural progenitor cells to neurons.

Authors:  James M Angelastro; Tatyana N Ignatova; Valery G Kukekov; Dennis A Steindler; George B Stengren; Cathy Mendelsohn; Lloyd A Greene
Journal:  J Neurosci       Date:  2003-06-01       Impact factor: 6.167

3.  ATF5 regulates the proliferation and differentiation of oligodendrocytes.

Authors:  Jeffrey L Mason; James M Angelastro; Tatyana N Ignatova; Valery G Kukekov; Grace Lin; Lloyd A Greene; James E Goldman
Journal:  Mol Cell Neurosci       Date:  2005-07       Impact factor: 4.314

Review 4.  Brain tumour stem cells.

Authors:  Angelo L Vescovi; Rossella Galli; Brent A Reynolds
Journal:  Nat Rev Cancer       Date:  2006-06       Impact factor: 60.716

5.  Cellular composition and cytoarchitecture of the adult human subventricular zone: a niche of neural stem cells.

Authors:  Alfredo Quiñones-Hinojosa; Nader Sanai; Mario Soriano-Navarro; Oscar Gonzalez-Perez; Zaman Mirzadeh; Sara Gil-Perotin; Richard Romero-Rodriguez; Mitchell S Berger; Jose Manuel Garcia-Verdugo; Arturo Alvarez-Buylla
Journal:  J Comp Neurol       Date:  2006-01-20       Impact factor: 3.215

6.  Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses.

Authors:  Marcela Assanah; Richard Lochhead; Alfred Ogden; Jeffrey Bruce; James Goldman; Peter Canoll
Journal:  J Neurosci       Date:  2006-06-21       Impact factor: 6.167

7.  Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.

Authors:  Yuan Zhu; Frantz Guignard; Dawen Zhao; Li Liu; Dennis K Burns; Ralph P Mason; Albee Messing; Luis F Parada
Journal:  Cancer Cell       Date:  2005-08       Impact factor: 31.743

8.  Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5.

Authors:  J M Angelastro; P D Canoll; J Kuo; M Weicker; A Costa; J N Bruce; L A Greene
Journal:  Oncogene       Date:  2006-02-09       Impact factor: 9.867

9.  Teratogenic and carcinogenic effects in the offspring after single injection of ethylnitrosourea to pregnant rats.

Authors:  H Druckrey; S Ivanković; R Preussmann
Journal:  Nature       Date:  1966-06-25       Impact factor: 49.962

10.  The development of experimental brain tumours a sequential light and electron microscope study of the subependymal plate. II. Microtumours.

Authors:  G J Pilkington; P L Lantos
Journal:  Acta Neuropathol       Date:  1979-03-15       Impact factor: 17.088

View more
  10 in total

1.  CD133+ niches and single cells in glioblastoma have different phenotypes.

Authors:  Karina Christensen; Henrik Daa Schrøder; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2010-12-24       Impact factor: 4.130

2.  Correlation of aberrant expression of CD133 with FHIT and malignant phenotype of colorectal adenocarcinoma.

Authors:  Hong Li; Po Zhao; Yang Lu; Yali Lu
Journal:  Int J Colorectal Dis       Date:  2012-02-09       Impact factor: 2.571

3.  CD133 stem cells in adult human brain.

Authors:  H T Hassan; X Zhai; J A Goodacre
Journal:  J Neurooncol       Date:  2008-06-21       Impact factor: 4.130

4.  Expression and targeting of transcription factor ATF5 in dog gliomas.

Authors:  D York; C D Sproul; N Chikere; P J Dickinson; J M Angelastro
Journal:  Vet Comp Oncol       Date:  2017-05-08       Impact factor: 2.613

5.  Overexpression of CD133 promotes drug resistance in C6 glioma cells.

Authors:  James M Angelastro; Michael W Lamé
Journal:  Mol Cancer Res       Date:  2010-07-27       Impact factor: 5.852

6.  Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma.

Authors:  Po Zhao; Yazhuo Li; Yali Lu
Journal:  BMC Cancer       Date:  2010-05-20       Impact factor: 4.430

Review 7.  The transcription factor ATF5: role in neurodevelopment and neural tumors.

Authors:  Lloyd A Greene; Hae Young Lee; James M Angelastro
Journal:  J Neurochem       Date:  2008-11-15       Impact factor: 5.372

8.  GSK3 inhibitor-BIO regulates proliferation of female germline stem cells from the postnatal mouse ovary.

Authors:  Y Hu; Y Bai; Z Chu; J Wang; L Wang; M Yu; Z Lian; J Hua
Journal:  Cell Prolif       Date:  2012-05-10       Impact factor: 6.831

9.  Regulated ATF5 loss-of-function in adult mice blocks formation and causes regression/eradication of gliomas.

Authors:  A Arias; M W Lamé; L Santarelli; R Hen; L A Greene; J M Angelastro
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

10.  Regression/eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide.

Authors:  Charles C Cates; Angelo D Arias; Lynn S Nakayama Wong; Michael W Lamé; Maxim Sidorov; Geraldine Cayanan; Douglas J Rowland; Jennifer Fung; Georg Karpel-Massler; Markus D Siegelin; Lloyd A Greene; James M Angelastro
Journal:  Oncotarget       Date:  2016-03-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.